Erdis, EdaYilmaz, MukaddesUcar, MahmutYucel, Birsen2024-10-262024-10-2620241300-7467https://doi.org/10.5505/tjo.2024.4380https://hdl.handle.net/20.500.12418/28302OBJECTIVE To evaluate, according to age, the acute toxicity and adverse events, such as interruption or cessation of chemoradiotherapy (CRT) and weight loss, in cancer patients. METHODS A total of 813 patients, 67% aged <65 years and 33% aged >= 65 years, were analyzed retrospectively. Toxicities were graded according to the acute radiation morbidity measurement criteria of the Radiation Therapy Oncology Group. RESULTS For all patients, 5% of the younger and 12% of the elderly patients (p<0.001) ended CRT, 1% of the younger and 4% of the elderly patients died during treatment (p=0.007). There were differences between the groups treated for brain cancer in terms of performance status (p=0.010), cessation (p=0.001), interruption (p=0.026), and death during treatment (p=0.043). For head and neck cancer, the results showed differences in comorbidity (p<0.001), performance status (p=0.017), and death during CRT (p=0.021). In the thoracic area, differences were found in comorbidity (p=0.015), CRT interruption (p=0.014), grade 1-2 skin toxicity (p=0.025), pharynx/esophagus (p=0.002), upper gastrointestinal tract (p=0.036), and hematocrit (p=0.032). For the abdominal area, differences were observed in comorbidity (p<0.001) and grade 1-2 platelet toxicity (p=0.029). For the pelvis, differences were seen in comorbidity (p<0.001), performance status (p=0.045), and CRT interruption (p=0.032). CONCLUSION Cessation, interruption, and death during CRT were observed more frequently in elderly patients.en10.5505/tjo.2024.4380info:eu-repo/semantics/closedAccessAcuteagedchemotherapyradiotherapyside effectArticle2-s2.0-85213324866WOS:001328877600001N/A